European Autoimmune Therapeutic Market to Surge Over the Next Decade
By Biotechdaily staff writers
Posted on 13 Feb 2007
The European market for drugs to treat autoimmune diseases is expected to increase from US$5.40 billion in 2006 to more than $18.74 billion by 2013. This prediction was recently issued by the marketing analysis firm Frost & Sullivan (London, UK).Posted on 13 Feb 2007
There are more than 70 different autoimmune diseases. In Europe more than 103 million people suffer from arthritis, including nearly two million with rheumatoid arthritis. The prevalence rate for multiple sclerosis (MS) in Europe is 83 per 100,000 with more than 4.3 per 100,000 new cases each year. Overall, the annual cost for caring for autoimmune disease patients is more than $65 billion.
"The growing patient population and the need for better treatment options are the major driving forces in market growth,” explained Frost & Sullivan industry analyst Sylvia Miriyam Findlay. "The complex nature of autoimmune diseases hinders the development of suitable therapeutics. The scenario is worsened by low awareness among patients and physicians as well as by improper communication about methods of effective disease management. Nevertheless, aggressive campaigns undertaken by the pharmaceutical companies to promote newer biologics are sparking interest among physicians and will propel revenue generation.”
Related Links:
Frost & Sullivan
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Laboratory Software
ArtelWare
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
